Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study
Open Access
- 25 July 2024
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (7) , 1315-1323
Abstract
Background: It is unknown whether the pre‐biologic treatment journey affects subsequent biologic drug survival.Objective: To examine the potential impact of a complex treatment journey on subsequent biologic drug survival in patients with psoriasis.Methods: The study utilized longitudinal data from Danish national registries and included all patients who, for the first time, initiated a biological treatment for psoriasis. Maximum follow‐up was 5 years and patients were included from 1 January 2010 to 30 June 2021. The study used three definitions of exposure to a complex treatment journey and the following conventional systemic treatments: acitretin, cyclosporine, dimethyl fumarate and methotrexate. The first definition was the cumulative number of treatment series. The second definition comprised the number of unique treatments. The third definition was time from the first conventional systemic treatment to biological therapy. Drug survival for the three definitions were illustrated using Kaplan–Meier curves and compared using log‐rank test. The sensitivity analysis largely confirmed these findings by grouping patients according to pharmacotherapy.Results: A total of 2496 patients were included in the study, with 1380 (55.3%) receiving adalimumab, 608 (24.4%) receiving ustekinumab, 271 (10.9%) receiving secukinumab, 166 (6.7%) receiving etanercept and 71 (2.8%) receiving infliximab. The mean age at initiation of biologics was 43.6 years (standard deviation (SD) 15.2 years), and most patients were male (62.9%). During the follow‐up of 5477 patient years, 1953 patients (78.2%) reached the main endpoint of discontinuation. Using a log‐rank test, the probability of remaining on treatment was unaffected by the three definitions of complexity of the treatment journey.Conclusion: None of the three exposures used to assess the complexity of the pre‐biologic treatment journey appeared to impact drug survival. As long as patients experience adequate disease control, these results suggest that conventional systemic treatment do not negatively impact the drug survival of subsequent biologics.Keywords
This publication has 28 references indexed in Scilit:
- Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization studyJEADV Clinical Practice, 2023
- Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort studyJournal of the American Academy of Dermatology, 2023
- Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisJAMA Dermatology, 2022
- Early intervention and disease memory in psoriasis: A literature reviewJEADV Clinical Practice, 2022
- Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled TrialJournal of Investigative Dermatology, 2022
- Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World StudyClinical Drug Investigation, 2021
- Psoriasis Prevalence in Adults in the United StatesJAMA Dermatology, 2021
- Long-term Outcomes and Prognosis in New-Onset PsoriasisJAMA Dermatology, 2021
- Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitisJournal of the American Academy of Dermatology, 2019
- Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Journal of Investigative Dermatology, 2018